Medical research

Unethical cancer trials in India may have led to 254 pointless deaths, claims American doctor

But researchers behind the study say that their findings have led to the implementation of large-scale cervical cancer screenings across the developing world.

Cervical cancer is recognised as one of the leading causes of cancer-related deaths among Indian women, killing an average of 72,000 women every year. Since 1997, however, at least 254 such deaths may have occurred because Indian women from lower-income groups were misinformed and not given basic pre-cancer screening tests even as they participated in research studies on cervical cancer.

This is a contention that Dr Eric Suba, an American pathologist and medical ethics proponent, has been making for several years in relation to three major long-term cervical cancer studies conducted in India between 1997 and 2012. All three studies received funding from prominent agencies in the United States: the US National Cancer Institute and the Bill and Melinda Gates Foundation. They were conducted by reputed institutions, namely the Tata Memorial Hospital in Mumbai and the World Health Organisation’s International Agency for Research on Cancer. They were conducted on 363,553 women – all from lower-income backgrounds – from Mumbai, Osmanabad district in Maharashtra and Dindigul district in Tamil Nadu.

Dr Suba’s contentions that the studies were "scientifically gratuitous" and ethically questionable have received considerable attention in international medical circles in the past few years, but were virtually unheard of in India.

On February 4, in a bid to draw more public attention to the controversy, Suba presented his analysis of the three studies in a lecture on the ethics of international public health research at Mumbai’s KEM Hospital. “In my opinion, these studies are the worst betrayals of science and ethics anywhere in the world in the 21st century,” alleged Suba in an interview with Scroll.in two days before his Mumbai lecture.

However, doctors from Tata Memorial Hospital, who were also present at the lecture, refuted Suba's claims and maintained that the studies were not unethical and have in fact led to the implementation of large-scale cervical cancer screenings across the developing world.

Putting women at risk of death?

Suba, who also heads the non-profit Viet/American Cervical Cancer Prevention Project, spent several years pushing for Pap smear screenings at the public-health level to prevent cervical cancer in Vietnam, and these efforts have borne fruit in the past 15 years. Across the world, he says, the medical community has long established that screening women for pre-cancerous lesions – through tests like the Pap smear, the HPV, or visual inspection with acetic acid (VIA) – and then treating those lesions, successfully prevents the development of cervical cancer later.

The main problem with the three studies in India, said Suba, is that they compared one group of women who received some form of screening for pre-cancerous lesions (the “intervention” group) with another group of women who received no screening at all (the “control” group). At the outset, the presence of the control group would imply that the studies broadly aimed to determine which group showed lower incidences of cervical cancer and lower rates of cancer deaths.

This, according to Suba, is an instance of “contemplating a question that has already been answered”, making the studies “scientifically pointless”: since screening is already a medically well-established means of detecting lesions that could later develop into cancer, it is obvious that the unscreened control groups would show higher incidences of cancer and higher death rates.

More disturbingly, says Suba, not screening women in the control group effectively meant letting potential lesions go undetected. If those lesions then developed into cervical cancer, the unscreened women would be diagnosed with the disease only at a later stage, when symptoms such as pelvic pain or vaginal bleeding became apparent. This is tantamount to putting participants at risk for cancer and death for the sake of a research study.

If Suba’s contention is legitimate, then the human cost of the three research trials is staggering. Of the 363,553 women who signed up for the trials, 138,624 were in the control group. Of these, 254 eventually died of cervical cancer. The intervention groups had a larger number of women – 224,929 – and of them, 208 died of cancer.

“All over the world, in cervical cancer trials, all participating women are screened, and different groups are created to study the effectiveness of different forms of screening tests,” said Suba, who believes the 138,624 women in the control groups of the studies were victims of misinformation, because no well-informed woman would wilfully choose the risks of cancer and death. “How could women choose to participate in the no-screening group and still be informed?”

Ironically, in a paper defending their stance, the doctors who conducted the studies claimed that the aim of the trials was to “provide an affordable, feasible, effective and evidence-based way of preventing cervical cancer in low and middle-income countries”. After Suba's February 4 lecture, Dr Rajendra Badwe, the director of the Tata Memorial Centre and one of the doctors on the team that conducted the Mumbai study, said that the aim of that study was "mortality reduction".

According to Suba, this actually legitimises his claim that the control group was, in fact, redundant, because deciding against screening women is not a way to prevent cervical cancer or reduce mortality.

Relative standards of care?

The three studies that Suba has been questioning in various academic papers since 2004 have been published in reputed medical journals. The doctors heading the trials have presented them at international forums as landmark studies that have led to the implementation of large-scale cervical cancer screening not just in India but also in other developing countries.

The doctors behind the studies – most notably Dr Rengaswamy Sankaranarayanan and Dr Surendra Shastri – have refuted and dismissed Suba’s allegations in a joint paper published in the Indian Journal of Medical Ethics in June 2014.

Their paper – a response to Suba’s own paper published in the same journal – argues that women in the control groups, in Mumbai as well as the other two studies, were not misinformed, but offered cancer education in their local languages.

“In our studies, the control group women were taught about cervical precursor lesions and cancer and how it can be detected early through screening and prevented, and they were given information on where they can seek screening,” said Dr Sankaranarayanan, the head of the cancer screening group of the International Agency for Research on Cancer, in an email to Scroll.in.

The US National Cancer Institute, which funded the Mumbai trials with grants amounting to $2.6 million from 1997 to 2014, also told Scroll.in that the participants were "educated" about cancer screening: "All women enrolled in the trial, in the experimental and control groups, received education about cancer screening and had access to cancer screening, if they sought it, at Tata Memorial Hospital."

These women were not actively screened for pre-cancerous lesions because the control group was meant to represent the regular standard of care for cervical cancer screening in India – as opposed to the intervention group, which would represent the higher standards of care given through one form of screening or the other.

In a 2014 interview with Global Oncology about the Mumbai study, Dr Surendra Shastri claimed that “since the standard of care for cervical cancer screening in India is no screening, we were ethically justified in having a no-screening control group”. For many medical ethicists, this itself is a controversial argument, as they believe that standards of care cannot be relative to the economic situation of a country.

Relative standards of care?

The ethical questions that Suba has raised have, in recent years, drawn more media attention and concern from organisations in the field of research ethics. In 2011, Suba filed a complaint against the Mumbai study by Tata Memorial Hospital with the US government’s Office for Human Research Protections. Unlike the Osmanabad and Dindigul district studies that were funded by the private Bill and Melinda Gates Foundation, the 15-year Mumbai study was funded by US government’s National Cancer Institute and could thus be investigated by another US government agency.

Suba’s complaint was that using death rates as a “yardstick” for the study’s success was unethical and “scientifically gratuitous”, and that the participating women – particularly those in the no-screening control group – were misinformed.

After investigating Suba’s complaint, the OHRP in 2012 found informed consent had not been satisfactorily taken from participating women. In an official letter to the Tata Memorial Hospital research team, the OHRP stated: "We determined that the subjects were not adequately informed of the alternative procedures or courses of treatment regarding screening for breast cancer or cervical cancer, namely, mammography and Pap testing...we determined that the subjects were not provided, in writing, with information about the possible alternative of seeking...screening outside of the research."

As per the OHRP’s requirements for corrective action, the women in the control group of the Mumbai study were eventually screened for lesions – but by this time, the 15-year study period was already over and several of the women had died.

“Through all of this, the researchers did not think it necessary to inform the women and their families about the fact that they had been misinformed,” said Suba.

Commercial interests alleged

At the start of the three studies, the researchers had contended that Pap smears were not a feasible screening option for lower and middle-income nations like India. They now claim that their studies have successfully popularised other screening tests like HPV and VIA in these nations, particularly VIA, an acetic acid-based test.

“After the three studies, there is increasingly more implementation of VIA-based screening in Tamil Nadu, Gujarat and Sikkim and in certain regions of India,” said Sankaranarayanan, who claims the studies have also led to the implementation of national-level screening programmes with VIA or HPV testing in at least 14 African countries and multiple Latin American nations. “These studies are regarded very highly in scientific and public health circles globally.”

Suba, meanwhile, is not so sure if the lives of low-income women in India have changed much since the trials. “The political purpose behind allowing such research is to give power to research and commercial interests, like companies producing HPV vaccines,” he alleged.

In the Osmanabad study, says Suba, researchers used an HPV test brand called Hybrid Capture 2, which is now being sold in India at a price of approximately Rs 2,000 per test. The Pap smear test, he claims, is much cheaper than that, at roughly Rs 80 per test, but this has not been prominently reported in the media. Pap smears, says Suba, are in fact a feasible means of detecting pre-cancerous lesions.

For now, Suba is waiting for the US Office of Research Integrity – another government-run ethics watchdog – to complete its investigation into the Mumbai study. The investigation began in May 2015 and may take a few years. “Meanwhile, I am trying to get leading physicians across the world to speak out about this,” he said.

We welcome your comments at letters@scroll.in.
Sponsored Content BY 

India’s urban water crisis calls for an integrated approach

We need solutions that address different aspects of the water eco-system and involve the collective participation of citizens and other stake-holders.

According to a UN report, around 1.2 billion people, or almost one fifth of the world’s population, live in areas where water is physically scarce and another 1.6 billion people, or nearly one quarter of the world’s population, face economic water shortage. They lack basic access to water. The criticality of the water situation across the world has in fact given rise to speculations over water wars becoming a distinct possibility in the future. In India the problem is compounded, given the rising population and urbanization. The Asian Development Bank has forecast that by 2030, India will have a water deficit of 50%.

Water challenges in urban India

For urban India, the situation is critical. In 2015, about 377 million Indians lived in urban areas and by 2030, the urban population is expected to rise to 590 million. Already, according to the National Sample Survey, only 47% of urban households have individual water connections and about 40% to 50% of water is reportedly lost in distribution systems due to various reasons. Further, as per the 2011 census, only 32.7% of urban Indian households are connected to a piped sewerage system.

Any comprehensive solution to address the water problem in urban India needs to take into account the specific challenges around water management and distribution:

Pressure on water sources: Rising demand on water means rising pressure on water sources, especially in cities. In a city like Mumbai for example, 3,750 Million Litres per Day (MLD) of water, including water for commercial and industrial use, is available, whereas 4,500 MLD is needed. The primary sources of water for cities like Mumbai are lakes created by dams across rivers near the city. Distributing the available water means providing 386,971 connections to the city’s roughly 13 million residents. When distribution becomes challenging, the workaround is to tap ground water. According to a study by the Centre for Science and Environment, 48% of urban water supply in India comes from ground water. Ground water exploitation for commercial and domestic use in most cities is leading to reduction in ground water level.

Distribution and water loss issues: Distribution challenges, such as water loss due to theft, pilferage, leaky pipes and faulty meter readings, result in unequal and unregulated distribution of water. In New Delhi, for example, water distribution loss was reported to be about 40% as per a study. In Mumbai, where most residents get only 2-5 hours of water supply per day, the non-revenue water loss is about 27% of the overall water supply. This strains the municipal body’s budget and impacts the improvement of distribution infrastructure. Factors such as difficult terrain and legal issues over buildings also affect water supply to many parts. According to a study, only 5% of piped water reaches slum areas in 42 Indian cities, including New Delhi. A 2011 study also found that 95% of households in slum areas in Mumbai’s Kaula Bunder district, in some seasons, use less than the WHO-recommended minimum of 50 litres per capita per day.

Water pollution and contamination: In India, almost 400,000 children die every year of diarrhea, primarily due to contaminated water. According to a 2017 report, 630 million people in the South East Asian countries, including India, use faeces-contaminated drinking water source, becoming susceptible to a range of diseases. Industrial waste is also a major cause for water contamination, particularly antibiotic ingredients released into rivers and soils by pharma companies. A Guardian report talks about pollution from drug companies, particularly those in India and China, resulting in the creation of drug-resistant superbugs. The report cites a study which indicates that by 2050, the total death toll worldwide due to infection by drug resistant bacteria could reach 10 million people.

A holistic approach to tackling water challenges

Addressing these challenges and improving access to clean water for all needs a combination of short-term and medium-term solutions. It also means involving the community and various stakeholders in implementing the solutions. This is the crux of the recommendations put forth by BASF.

The proposed solutions, based on a study of water issues in cities such as Mumbai, take into account different aspects of water management and distribution. Backed by a close understanding of the cost implications, they can make a difference in tackling urban water challenges. These solutions include:

Recycling and harvesting: Raw sewage water which is dumped into oceans damages the coastal eco-system. Instead, this could be used as a cheaper alternative to fresh water for industrial purposes. According to a 2011 World Bank report, 13% of total freshwater withdrawal in India is for industrial use. What’s more, the industrial demand for water is expected to grow at a rate of 4.2% per year till 2025. Much of this demand can be met by recycling and treating sewage water. In Mumbai for example, 3000 MLD of sewage water is released, almost 80% of fresh water availability. This can be purified and utilised for industrial needs. An example of recycled sewage water being used for industrial purpose is the 30 MLD waste water treatment facility at Gandhinagar and Anjar in Gujarat set up by Welspun India Ltd.

Another example is the proposal by Navi Mumbai Municipal Corporation (NMMC) to recycle and reclaim sewage water treated at its existing facilities to meet the secondary purposes of both industries and residential complexes. In fact, residential complexes can similarly recycle and re-use their waste water for secondary purposes such as gardening.

Also, alternative rain water harvesting methods such as harvesting rain water from concrete surfaces using porous concrete can be used to supplement roof-top rain water harvesting, to help replenish ground water.

Community initiatives to supplement regular water supply: Initiatives such as community water storage and decentralised treatment facilities, including elevated water towers or reservoirs and water ATMs, based on a realistic understanding of the costs involved, can help support the city’s water distribution. Water towers or elevated reservoirs with onsite filters can also help optimise the space available for water distribution in congested cities. Water ATMs, which are automated water dispensing units that can be accessed with a smart card or an app, can ensure metered supply of safe water.

Testing and purification: With water contamination being a big challenge, the adoption of affordable and reliable multi-household water filter systems which are electricity free and easy to use can help, to some extent, access to safe drinking water at a domestic level. Also, the use of household water testing kits and the installation of water quality sensors on pipes, that send out alerts on water contamination, can create awareness of water contamination and drive suitable preventive steps.

Public awareness and use of technology: Public awareness campaigns, tax incentives for water conservation and the use of technology interfaces can also go a long way in addressing the water problem. For example, measures such as water credits can be introduced with tax benefits as incentives for efficient use and recycling of water. Similarly, government water apps, like that of the Municipal Corporation of Greater Mumbai, can be used to spread tips on water saving, report leakage or send updates on water quality.

Collaborative approach: Finally, a collaborative approach like the adoption of a public-private partnership model for water projects can help. There are already examples of best practices here. For example, in Netherlands, water companies are incorporated as private companies, with the local and national governments being majority shareholders. Involving citizens through social business models for decentralised water supply, treatment or storage installations like water ATMs, as also the appointment of water guardians who can report on various aspects of water supply and usage can help in efficient water management. Grass-root level organizations could be partnered with for programmes to spread awareness on water safety and conservation.

For BASF, the proposed solutions are an extension of their close engagement with developing water management and water treatment solutions. The products developed specially for waste and drinking water treatment, such as Zetag® ULTRA and Magnafloc® LT, focus on ensuring sustainability, efficiency and cost effectiveness in the water and sludge treatment process.

BASF is also associated with operations of Reliance Industries’ desalination plant at Jamnagar in Gujarat.The thermal plant is designed to deliver up to 170,000 cubic meters of processed water per day. The use of inge® ultrafiltration technologies allows a continuous delivery of pre-filtered water at a consistent high-quality level, while the dosage of the Sokalan® PM 15 I protects the desalination plant from scaling. This combination of BASF’s expertise minimises the energy footprint of the plant and secures water supply independent of the seasonal fluctuations. To know more about BASF’s range of sustainable solutions and innovative chemical products for the water industry, see here.

This article was produced by the Scroll marketing team on behalf of BASF and not by the Scroll editorial team.